233 related articles for article (PubMed ID: 20836618)
1. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Isaacs JT
Expert Opin Investig Drugs; 2010 Oct; 19(10):1235-43. PubMed ID: 20836618
[TBL] [Abstract][Full Text] [Related]
2. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
3. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
[TBL] [Abstract][Full Text] [Related]
4. A review of tasquinimod in the treatment of advanced prostate cancer.
Williamson SC; Hartley AE; Heer R
Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
[TBL] [Abstract][Full Text] [Related]
5. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
George S; Pili R
Curr Oncol Rep; 2013 Apr; 15(2):65-8. PubMed ID: 23334511
[TBL] [Abstract][Full Text] [Related]
6. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
Bratt O; Häggman M; Ahlgren G; Nordle O; Björk A; Damber JE
Br J Cancer; 2009 Oct; 101(8):1233-40. PubMed ID: 19755981
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
9. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
10. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials.
Gong P; Liu H; Liu X; Zhou G; Liu M; Yang X; Xiong W; Wang Q; Ma J; Ren Z; He M; Zhang X
Medicine (Baltimore); 2018 Nov; 97(46):e13204. PubMed ID: 30431595
[TBL] [Abstract][Full Text] [Related]
12. Tasquinimod: a novel drug in advanced prostate cancer.
Osanto S; van Poppel H; Burggraaf J
Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
[TBL] [Abstract][Full Text] [Related]
13. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
15. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.
Gupta N; Al Ustwani O; Shen L; Pili R
Onco Targets Ther; 2014; 7():223-34. PubMed ID: 24600234
[TBL] [Abstract][Full Text] [Related]
17. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
18. Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.
Mehta AR; Armstrong AJ
Ther Adv Urol; 2016 Feb; 8(1):9-18. PubMed ID: 26834836
[TBL] [Abstract][Full Text] [Related]
19. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
20. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
